Centessa Pharmaceuticals Plc Stock Price, News & Analysis

Spotlight Therapeutics has appointed Antoine Yver, M.D., M.Sc., to its Board of Directors, enhancing its leadership with over 30 years of experience in drug development. Dr. Yver is recognized for his influential role in bringing significant cancer treatments like Enhertu, Tagrisso, and Lynparza to market. This strategic move aligns with Spotlight's mission to advance its TAGE platform for gene editing therapies aimed at various diseases. The company's growth trajectory is expected to benefit from Dr. Yver's expertise in oncology and immunology.

Centessa Pharmaceuticals (Nasdaq: CNTA) announced the appointment of Mathias Hukkelhoven, Ph.D., to its Board of Directors, effective July 1, 2022. Hukkelhoven, with extensive experience in global regulatory and drug development, previously held leadership roles at Bristol Myers Squibb and Novartis. His expertise is expected to enhance Centessa's efforts in advancing its rare disease and immuno-oncology programs. Additionally, Aaron Kantoff resigned from the Board but will remain as an advisor. This leadership transition comes at a strategic time as the company aims to fulfill unmet medical needs.

Centessa Pharmaceuticals (Nasdaq: CNTA) announced participation in two upcoming investor conferences. The first is the Jefferies Healthcare Conference, scheduled for June 9, 2022, featuring a fireside chat webcast at 4:30 PM ET. The second is the Goldman Sachs 43rd Annual Global Healthcare Conference on June 15, 2022, with a fireside chat at 8:00 AM PT / 11:00 AM ET. Live webcasts and archived recordings will be accessible in the investor relations section of the Centessa website.

Centessa Pharmaceuticals (CNTA) announced promising preclinical results for LB101, a PD-L1xCD47 LockBody, at the 2022 ASCO Annual Meeting. The data showed that LB101, delivered systemically as a single-agent, resulted in significant tumor regressions in a mouse model, with 26 out of 32 tumors eradicated. Importantly, no toxicity was observed, suggesting a favorable safety profile. The company plans to advance LB101 into clinical trials by late 2022, aiming to transform immuno-oncology treatments.

Centessa Pharmaceuticals (Nasdaq: CNTA) announced the discontinuation of lixivaptan's development for Autosomal Dominant Polycystic Kidney Disease (ADPKD) due to safety concerns, specifically elevated ALT/AST levels observed in the ALERT Study. This strategic move is expected to significantly decrease cash burn and extend the company’s financial runway into 2026. Centessa aims to focus on its rare disease and immuno-oncology pipeline, anticipating multiple clinical proof of concept readouts in the next 12 to 24 months.

Centessa Pharmaceuticals (CNTA) has outlined its progress in advancing its rare disease and immuno-oncology pipeline toward its '4x24' goal, aiming for four registrational programs in 2024. Key updates include the ongoing registrational ACTION Study for lixivaptan targeting ADPKD and a Phase 1 study for ZF874 in AATD. As of March 31, 2022, Centessa reported cash and cash equivalents of $544.5 million, ensuring operational funding through mid-2024. The first quarter saw R&D expenses of $36.9 million and a net loss attributable to ordinary shareholders of $54.5 million.

Scorpion Therapeutics has appointed Dr. Saurabh Saha to its Board of Directors. Dr. Saha, CEO of Centessa Pharmaceuticals, has over 20 years of experience in biopharmaceutical research. This strategic appointment aligns with Scorpion's Precision Oncology 2.0 strategy, aiming to enhance cancer treatment development. Dr. Saha's expertise is expected to be pivotal as the company prepares for investigational new drug applications for its lead programs in the upcoming year.

Centessa Pharmaceuticals (NASDAQ: CNTA) reported a net loss of $60.8 million for Q4 2021 and $381.1 million for the full year, primarily driven by $220 million in R&D expenses from acquisitions. The company holds $595.1 million in cash as of December 31, 2021, aimed to fund operations into early 2024.

The company focuses on rare diseases and immuno-oncology, with SerpinPC registrational studies planned for Hemophilia B in 2H 2022, and Lixivaptan in a Phase 3 trial for ADPKD. Centessa's '4x24' goal aims for four registrational programs by 2024.

Centessa Pharmaceuticals (Nasdaq: CNTA) announced that CEO Saurabh Saha will present at the Guggenheim Genomic Medicines & Rare Disease Day on March 31, 2022, at 11:00 AM ET. Investors can access the live webcast and archived recordings on the company’s investor relations website.

This presentation aligns with Centessa's mission to develop impactful medicines across various therapeutic areas, including oncology, hematology, and neuroscience. For more details, visit Centessa's website.